Published in Ann Oncol on August 01, 2007
Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med (2009) 2.73
Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol (2008) 2.61
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem (2010) 1.87
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs (2008) 1.56
The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One (2009) 1.40
Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology (2009) 1.39
Integrin targeted therapeutics. Theranostics (2011) 1.36
Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol (2011) 1.32
Cancer treatment using peptides: current therapies and future prospects. J Amino Acids (2012) 1.23
Integrin alpha(v)beta(3)-Targeted Cancer Therapy. Drug Dev Res (2008) 1.17
Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response (2010) 1.16
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res (2008) 1.10
Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone (2010) 1.09
Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer (2011) 1.06
iACP: a sequence-based tool for identifying anticancer peptides. Oncotarget (2016) 0.97
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs (2010) 0.95
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer (2011) 0.93
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs (2010) 0.91
Mesenchymal migration as a therapeutic target in glioblastoma. J Oncol (2010) 0.89
Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent. PLoS One (2010) 0.88
RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis. Cancers (Basel) (2012) 0.87
Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities. PLoS One (2010) 0.86
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models. Cancer Sci (2014) 0.80
Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential. Toxicon (2011) 0.79
Insulin-like growth factor binding protein-3 inhibits cell adhesion via suppression of integrin β4 expression. Oncotarget (2015) 0.78
Suppression of β3-integrin in mice triggers a neuropilin-1-dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesis. Dis Model Mech (2015) 0.76
Differential growth inhibition of cerebral metastases by anti-angiogenic compounds. Anticancer Res (2014) 0.75
Safety of targeting tumor endothelial cell antigens. J Transl Med (2016) 0.75
Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions. J Bacteriol (1999) 10.31
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J (2001) 8.90
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (1992) 7.02
Quality collaboratives: lessons from research. Qual Saf Health Care (2002) 6.78
Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature (1999) 5.77
Effects of instructions and reinforcement-feedback on human operant behavior maintained by fixed-interval reinforcement. J Exp Anal Behav (1969) 5.38
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
Transfer of thymidine kinase to thymidine kinaseless L cells by infection with ultraviolet-irradiated herpes simplex virus. J Virol (1971) 5.13
Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J Exp Med (1994) 4.91
The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J (1997) 4.65
beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci (1992) 4.10
Simplified method for dissolved DNA determination in aquatic environments. Appl Environ Microbiol (1986) 3.69
Survival, functional limitations, and self-rated health in the NHANES I Epidemiologic Follow-up Study, 1992. First National Health and Nutrition Examination Survey. Am J Epidemiol (2000) 3.58
Successful linkage of medical care and community services for HIV-positive offenders being released from prison. J Urban Health (2001) 3.49
Esophageal dilation after laparoscopic adjustable gastric banding. Surg Endosc (2007) 3.27
Electrophoresis of thymidine kinase activity synthesized by cells transformed by herpes simplex virus. Virology (1972) 3.05
A recyclable Candida albicans URA3 cassette for PCR product-directed gene disruptions. Yeast (2000) 2.90
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res (1998) 2.67
Reinforcement of human observing behavior by a stimulue correlated with extinction or increased effort. J Exp Anal Behav (1980) 2.66
Dosage effects on gene expression in a maize ploidy series. Genetics (1996) 2.43
Human, free-operant avoidance of "time out" from monetary reinforcement. J Exp Anal Behav (1966) 2.39
High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol (2002) 2.33
The effect of multiple reexcisions on the risk of local recurrence after breast conserving surgery. Ann Surg Oncol (2007) 2.32
Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia (2002) 2.29
Coordinate suppression of mutations caused by Robertson's mutator transposons in maize. Genetics (1994) 2.28
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Brain aging and midlife tofu consumption. J Am Coll Nutr (2000) 2.25
Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst (2001) 2.24
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol (2005) 2.23
Striated flagellar roots: isolation and partial characterization of a calcium-modulated contractile organelle. J Cell Biol (1984) 2.15
Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol (2001) 2.12
Sec-independent protein translocation by the maize Hcf106 protein. Science (1997) 2.09
High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology (2005) 2.07
Diagnostic value of the proton pump inhibitor test for gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther (2006) 2.07
Evaluation of quality improvement programmes. Qual Saf Health Care (2002) 2.06
Bacteria lacking a multidrug pump: a sensitive tool for drug discovery. Proc Natl Acad Sci U S A (1998) 2.01
Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury. Crit Care Med (2000) 1.98
Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA (1999) 1.96
Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res (1999) 1.95
E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis. Mol Cell Biol (2001) 1.91
Neuromotor precursors of schizophrenia. Schizophr Bull (1994) 1.88
Assessing guidelines for use in family practice. J Fam Pract (2001) 1.87
Environmental factors and the risk of salivary gland cancer. Epidemiology (1997) 1.86
Albumin Yanomama-2, a 'private' polymorphism of serum albumin. Ann Hum Genet (1974) 1.80
Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. Eur Heart J (2003) 1.79
Hox-5.1 defines a homeobox-containing gene locus on mouse chromosome 2. Proc Natl Acad Sci U S A (1988) 1.79
Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Oncogene (1995) 1.78
A new homeo-box is present in overlapping cosmid clones which define the mouse Hox-1 locus. EMBO J (1986) 1.77
Report on activities and attitudes of organizations active in the clinical practice guidelines field. CMAJ (1995) 1.76
Successful use of oral diazoxide in the treatment of severe toxaemia of pregnancy. Br Med J (1972) 1.76
Evaluation of common breast problems: guidance for primary care providers. CA Cancer J Clin (1998) 1.72
Choosing among health insurance options: a study of new employees. Inquiry (1990) 1.72
Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene (2001) 1.68
Methodology and feasibility of a home-based examination in disabled older women: the Women's Health and Aging Study. J Gerontol A Biol Sci Med Sci (1997) 1.66
Immunosuppressive and monooxygenase induction activities of polychlorinated diphenyl ether congeners in C57BL/6N mice: quantitative structure-activity relationships. Toxicol Appl Pharmacol (1990) 1.65
Clock control of human performance on avoidance and fixed-interval schedules. J Exp Anal Behav (1976) 1.64
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol (2008) 1.64
The genetic structure of a tribal population, the Yanomama Indians. IX. Gene frequencies for 18 serum protein and erythrocyte enzyme systems in the Yanomama and five neighboring tribes: nine new variants. Am J Hum Genet (1973) 1.59
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Drug design by machine learning: support vector machines for pharmaceutical data analysis. Comput Chem (2001) 1.59
Experimental designs. Behav Anal (1990) 1.58
Psychological stress and the passage of a standard meal through the stomach and small intestine in man. Gut (1983) 1.57
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol (2000) 1.57
Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene (2006) 1.56
Subclavian arterial injury associated with blunt trauma. Vasc Surg (2001) 1.56
The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer (1998) 1.54
Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol (2000) 1.54
Major depression and all-cause mortality among white adults in the United States. Ann Epidemiol (1997) 1.50
T cell receptor (TCR) beta chain homodimers on the surface of immature but not mature alpha, gamma, delta chain deficient T cell lines. EMBO J (1992) 1.49
Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull World Health Organ (2003) 1.49
Magnetic resonance imaging of children without sedation: preparation with simulation. J Am Acad Child Adolesc Psychiatry (1997) 1.46
Facilitation and suppression of human loss-avoidance by signaled, unavoidable loss. J Exp Anal Behav (1968) 1.46
Ca2+ channel activation and membrane depolarization mediated by Cl- channels in response to noradrenaline in vascular myocytes. Br J Pharmacol (1991) 1.46
Effect of malnutrition at the time of diagnosis on the survival of children treated for cancer in El Salvador and Northern Brazil. J Pediatr Hematol Oncol (2000) 1.44
Heart transplantation for tumor. Ann Thorac Surg (1993) 1.44
Suppression of behavior by timeout punishment when suppression results in loss of positive reinforcement. J Exp Anal Behav (1968) 1.44
Reinforcement magnitude and pausing on progressive-ratio schedules. J Exp Anal Behav (1992) 1.43
Kinetics and free energy gaps of electron-transfer reactions in Rhodobacter sphaeroides reaction centers. Biochemistry (1993) 1.43
Comprehensive MR imaging protocol for stroke management: tissue sodium concentration as a measure of tissue viability in nonhuman primate studies and in clinical studies. Radiology (1999) 1.42
Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia (2009) 1.41
The prognosis and incidence of social phobia in an elderly population. A 5-year follow-up. Acta Psychiatr Scand (2010) 1.41
Genetic studies of the Macushi and Wapishana Indians. I. Rare genetic variants and a "private polymorphism' of esterase A. Hum Genet (1977) 1.41
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol (1996) 1.41
Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev (1999) 1.40
Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol (1997) 1.39
Insurance policies for prophylactic surgery: to cover or not to cover? Ann Surg Oncol (2000) 1.39
PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat (2003) 1.39
Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells. Genes Dev (1995) 1.37
Oedema Disease (Entero-Toxaemia) In Swine-II. Experiments Conducted In A Susceptible Herd. Can J Comp Med Vet Sci (1955) 1.37
Endoplasmic reticulum dynamics, inheritance, and cytoskeletal interactions in budding yeast. Mol Biol Cell (2002) 1.37
The relationship between meeting patients' information needs and their satisfaction with hospital care and general health status outcomes. Int J Qual Health Care (1996) 1.37
Physical activity patterns associated with cardiorespiratory fitness and reduced mortality: the Aerobics Center Longitudinal Study. Am J Public Health (1998) 1.36
Solid phase synthesis of somatostatin-28. Biochem Biophys Res Commun (1980) 1.34
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol (1999) 1.32
The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl (1985) 1.31